参考文献/References:
[1] Yelamanchili VS,Hajouli S. Coronary artery stents[M]. In:StatPearls[Internet].Treasure Island(FL):StatPearls Publishing:2022. [2] Chaturvedula S,Diver D,Vashist A. Antiplatelet therapy in coronary artery disease:a daunting dilemma[J]. J Clin Med,2018,7(4):74.
[3] Saito Y,Kobayashi Y. Update on antithrombotic therapy after percutaneous coronary intervention[J]. Intern Med,2020,59(3):311-321.
[4] Silvain J,Lattuca B,Beygui F,et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention(ALPHEUS):a randomised,open-label,phase 3b trial[J]. Lancet,2020,396(10264):1737-1744.
[5] Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.
[6] Thiele H,Desch S,de Waha S. Acute myocardial infarction in patients with ST-segment elevation myocardial infarction:ESC guidelines 2017[J]. Herz,2017,42(8):728-738.
[7] Collet JP. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1289-1367.
[8] Patti G,Micieli G,Cimminiello C,et al. The role of clopidogrel in 2020:a reappraisal[J]. Cardiovasc Ther,2020,2020:8703627.
[9] Zhou J,Tan Y,Liu C,et al. Ticagrelor versus clopidogrel in patients with late or very late stent thrombosis[J]. Cardiovasc Drugs Ther,2020,34(5):677-684.
[10] Turgeon RD,Koshman SL,Youngson E,et al. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. JAMA Intern Med,2020,180(3):420-428.
[11] Hamilos M,Kanakakis J,Anastasiou I,et al. Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis:the MIRTOS trial[J]. EuroIntervention,2021,16(14):1163-1169.
[12] Fujisaki T,Kuno T,Ando T,et al. Potent P2Y12 inhibitors versus clopidogrel in elderly patients with acute coronary syndrome:systematic review and meta-analysis[J]. Am Heart J,2021,237:34-44.
[13] Price MJ,Berger PB,Teirstein PS,et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J]. JAMA,2011,305(11):1097-1105.
[14] Xu Q,Sun Y,Zhang Y,et al. Effect of a 180 mg ticagrelor loading dose on myocardial necrosis in patients undergoing elective percutaneous coronary intervention:a preliminary study[J]. Cardiol J,2017,24(1):15-24.
[15] Kumari P,Ranwa BL. Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions[J]. Indian Heart J,2018,70(suppl 3):S319-S322.
[16] Dawson LP,Chen D,Dagan M,et al. Assessment of pretreatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in patients with non-ST elevation acute coronary syndromes:a systematic review and meta-analysis[J]. JAMA Netw Open,2021,4(11):e2134322.
[17] Sharma SK. Oral antiplatelet therapy in PCI patients[J]. Catheter Cardiovasc Interv,2010,75 Suppl 1:S7-S14.
[18] Schrör K. Why we should not skip aspirin in cardiovascular prevention[J]. Hamostaseologie,2016,36(1):33-43.
[19] Alexopoulos D,Mpahara A,Kassimis G. Omitting aspirin in PCI patients:myth or reality?[J]. Cardiovasc Drugs Ther,2019,33(6):711-724.
[20] Faxon DP. Tailored antiplatelet therapy in patients undergoing PCI:is rapid bedside genetic testing the answer?[J]. JACC Basic Transl Sci,2020,5(5):429-431.
[21] Liu J,Qin L,Xi S,et al. Genotype-guided personalization of antiplatelet treatment:a meta-analysis of patients with ACS or undergoing PCI[J]. Thromb Res,2019,179:87-94.
[22] Dang W,Wang J,Zhang Q,et al. Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function:a one-center retrospective cohort study[J]. Medicine(Baltimore),2021,100(16):25601.
[23] Yan XQ,Zhang C,Shi HY,et al. Platelet-fibrin clot strength measured by thromboelastography could predict hypercoagulability and antiplatelet effects in patients after percutaneous coronary intervention[J]. Ann Palliat Med,2021,10(3):2448-2457.
[24] Zheng YY,Wu TT,Yang Y,et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention:a randomized controlled clinical trial[J]. Eur Heart J Cardiovasc Pharmacother,2020,6(4):211-221.
[25] O’Donoghue ML,Sabatine MS. Aspirin or P2Y12 inhibition:establishing the cornerstone of antiplatelet therapy after stenting[J]. Eur Heart J,2021,42(4):320-322.
[26] Valgimigli M,Cao D,Angiolillo DJ,et al. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI[J]. J Am Coll Cardiol,2021,78(21):2060-2072.
[27] Bianco M,Bernardi A,D’Ascenzo F,et al. Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention:a survey and systematic review[J]. Circ Cardiovasc Interv,2016,9(1):e002896.
[28] Barillà F,Pulcinelli FM,Mangieri E,et al. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention[J]. Platelets,2013,24(3):183-188.
[29] Byrne RA,Joner M,Kastrati A. Stent thrombosis and restenosis:what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014[J]. Eur Heart J,2015,36(47):3320-3331.
相似文献/References:
[1]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(1):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[2]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(1):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[3]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(1):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[4]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(1):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(1):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[6]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(1):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[7]管翔 王宇 张成糕 周健 张艺 李庆国.经皮心室辅助装置在复杂高危冠状动脉介入治疗中的应用进展[J].心血管病学进展,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
GUAN Xiang,WANG Yu,ZHANG Chenggao,et al.Application Progress of Percutaneous Ventricular Assist Device in Complex High-Risk Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(1):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
[8]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(1):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
[9]宋艳华 来春林 杨五小.急性 ST段抬高型心肌梗死患者微血管功能障碍的研究进展[J].心血管病学进展,2022,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
SONG Yanhua,LAI Chunlin,YANG Wuxiao.Microvascular Dysfunction in Patients with Acute ST-Segment?levation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2022,(1):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
[10]纪欣强 王凡.肥胖悖论与经皮冠状动脉介入治疗预后相关性的研究进展[J].心血管病学进展,2022,(7):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
JI XinqiangWANG Fan.Correlation Between Obesity Paradox and Prognosis of Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(1):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]